Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 04 2023
12 04 2023
Historique:
received:
02
11
2022
accepted:
06
04
2023
medline:
14
4
2023
entrez:
12
4
2023
pubmed:
13
4
2023
Statut:
epublish
Résumé
Glioblastoma multiforme (GBM) belongs to most aggressive and invasive primary brain tumor in adults whose prognosis and survival remains poor. Potential new treatment modalities include targeting the cytoskeleton. In our study, we demonstrated that repurposed drug flubendazole (FLU) significantly inhibits proliferation and survival of GBM cells. FLU exerted its effect by affecting microtubule structure and our results also suggest that FLU influences tubulins expression to a certain degree. Moreover, FLU effects decreased activation of STAT3 and also partially inhibited its expression, leading to upregulation of p53 signaling pathway and subsequent cell cycle arrest at G2/M phase as well as caspase-dependent cell death in GBM cells. These results suggest FLU as a promising agent to be used in GBM treatment and prompting further testing of its effects on GBM.
Identifiants
pubmed: 37045903
doi: 10.1038/s41598-023-33047-9
pii: 10.1038/s41598-023-33047-9
pmc: PMC10097688
doi:
Substances chimiques
flubendazole
R8M46911LR
Mebendazole
81G6I5V05I
STAT3 protein, human
0
STAT3 Transcription Factor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5993Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Ramos, A. D., Magge, R. S. & Ramakrishna, R. Molecular pathogenesis and emerging treatment for glioblastoma. World Neurosurg. 116, 495–504 (2018).
doi: 10.1016/j.wneu.2018.04.021
pubmed: 30049044
de Gooijer, M. C. et al. An experimenter’s guide to glioblastoma invasion pathways. Trends Mol. Med. 24(9), 763–780 (2018).
doi: 10.1016/j.molmed.2018.07.003
pubmed: 30072121
Strobel, H. et al. Temozolomide and other alkylating agents in glioblastoma therapy. Biomedicines 7(3), 1 (2019).
doi: 10.3390/biomedicines7030069
Miranda, A., et al. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches. Int. J. Pharm. 531(1), 372–388 (2017).
Schreck, K.C., & Grossman, S.A. Role of temozolomide in the treatment of cancers involving the central nervous system. Oncology (Williston Park) 32(11), 555–60, 569 (2018).
Balca-Silva, J. et al. Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies. Semin. Cancer Biol. 58, 130–141 (2019).
doi: 10.1016/j.semcancer.2018.09.007
pubmed: 30266571
Szopa, W. et al. Diagnostic and therapeutic biomarkers in glioblastoma: Current status and future perspectives. Biomed. Res. Int. 2017, 8013575 (2017).
doi: 10.1155/2017/8013575
pubmed: 28316990
pmcid: 5337853
Katsetos, C. D. et al. Emerging microtubule targets in glioma therapy. Semin. Pediatr. Neurol. 22(1), 49–72 (2015).
doi: 10.1016/j.spen.2015.03.009
pubmed: 25976261
Skalli, O. et al. Astrocytoma grade IV (glioblastoma multiforme) displays 3 subtypes with unique expression profiles of intermediate filament proteins. Hum. Pathol. 44(10), 2081–2088 (2013).
doi: 10.1016/j.humpath.2013.03.013
pubmed: 23791210
Zottel, A. et al. Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy: A systematic review. Crit. Rev. Oncol. Hematol. 160, 103283 (2021).
doi: 10.1016/j.critrevonc.2021.103283
pubmed: 33667657
Katsetos, C. D., Draber, P. & Kavallaris, M. Targeting betaIII-tubulin in glioblastoma multiforme: From cell biology and histopathology to cancer therapeutics. Anticancer Agents Med. Chem. 11(8), 719–728 (2011).
doi: 10.2174/187152011797378760
pubmed: 21707498
Katsetos, C. D. et al. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme II. gamma-Tubulin. J. Cell Physiol. 221(3), 514–520 (2009).
doi: 10.1002/jcp.21884
pubmed: 19650077
Katsetos, C. D. et al. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. J. Cell Physiol. 221(3), 505–513 (2009).
doi: 10.1002/jcp.21870
pubmed: 19650075
Hanusova, V. et al. Potential anti-cancer drugs commonly used for other indications. Curr. Cancer Drug Targets 15(1), 35–52 (2015).
doi: 10.2174/1568009615666141229152812
pubmed: 25544649
Michaelis, M. et al. Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen. Sci. Rep. 5, 8202 (2015).
doi: 10.1038/srep08202
pubmed: 25644037
pmcid: 4314641
Canova, K., Rozkydalova, L. & Rudolf, E. Anthelmintic Flubendazole and its potential use in anticancer therapy. Acta Med. (Hradec Kralove) 60(1), 5–11 (2017).
doi: 10.14712/18059694.2017.44
Zhou, X. et al. Flubendazole inhibits glioma proliferation by G2/M cell cycle arrest and pro-apoptosis. Cell Death Discov. 4, 18 (2018).
doi: 10.1038/s41420-017-0017-2
pubmed: 30062063
pmcid: 5841417
Ren, L. W. et al. Benzimidazoles induce concurrent apoptosis and pyroptosis of human glioblastoma cells via arresting cell cycle. Acta Pharmacol. Sin. 43(1), 194–208 (2022).
doi: 10.1038/s41401-021-00752-y
pubmed: 34433903
Chen, C. et al. Flubendazole plays an important anti-tumor role in different types of cancers. Int. J. Mol. Sci. 23(1), 1 (2022).
doi: 10.3390/ijms23010519
Lin, S. et al. Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy. J. Exp. Clin. Cancer Res. 38(1), 293 (2019).
doi: 10.1186/s13046-019-1303-z
pubmed: 31287013
pmcid: 6615228
Oh, E. et al. Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition. Int. J. Cancer 143(8), 1978–1993 (2018).
doi: 10.1002/ijc.31585
pubmed: 29744876
Hong, S. & Song, M. R. STAT3 but not STAT1 is required for astrocyte differentiation. PLoS ONE 9(1), e86851 (2014).
doi: 10.1371/journal.pone.0086851
pubmed: 24466267
pmcid: 3900679
Gray, G. K. et al. NF-κB and STAT3 in glioblastoma: Therapeutic targets coming of age. Expert Rev. Neurother. 14(11), 1293–1306 (2014).
doi: 10.1586/14737175.2014.964211
pubmed: 25262780
pmcid: 4350260
Luwor, R. B., Stylli, S. S. & Kaye, A. H. The role of Stat3 in glioblastoma multiforme. J. Clin. Neurosci. 20(7), 907–911 (2013).
doi: 10.1016/j.jocn.2013.03.006
pubmed: 23688441
Niu, G. et al. Role of Stat3 in regulating p53 expression and function. Mol. Cell Biol. 25(17), 7432–7440 (2005).
doi: 10.1128/MCB.25.17.7432-7440.2005
pubmed: 16107692
pmcid: 1190305
Skarkova, V. et al. The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior. Int. J. Mol. Sci. 20(18), 1 (2019).
doi: 10.3390/ijms20184630
Bai, R. Y. et al. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 13(9), 974–982 (2011).
doi: 10.1093/neuonc/nor077
pubmed: 21764822
pmcid: 3158014
Khachigian, L. M. Emerging insights on functions of the anthelmintic flubendazole as a repurposed anticancer agent. Cancer Lett 522, 57–62 (2021).
doi: 10.1016/j.canlet.2021.09.013
pubmed: 34520820
Abbassi, R. H. et al. Lower tubulin expression in glioblastoma stem cells attenuates efficacy of microtubule-targeting agents. ACS Pharmacol. Transl. Sci. 2(6), 402–413 (2019).
doi: 10.1021/acsptsci.9b00045
pubmed: 32259073
pmcid: 7089104
Spagnuolo, P. A. et al. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 115(23), 4824–4833 (2010).
doi: 10.1182/blood-2009-09-243055
pubmed: 20348394
Mc Gee, M. M. Targeting the mitotic catastrophe signaling pathway in cancer. Mediat. Inflamm. 2015, 146282 (2015).
doi: 10.1155/2015/146282
Carro, M. S. et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463(7279), 318–325 (2010).
doi: 10.1038/nature08712
pubmed: 20032975
Ndubuisi, M. I. et al. Cellular physiology of STAT3: Where’s the cytoplasmic monomer?. J. Biol. Chem. 274(36), 25499–25509 (1999).
doi: 10.1074/jbc.274.36.25499
pubmed: 10464281
Yan, B. et al. STAT3 association with microtubules and its activation are independent of HDAC6 activity. DNA Cell Biol. 34(4), 290–295 (2015).
doi: 10.1089/dna.2014.2713
pubmed: 25621430
pmcid: 4390050